Menu
Search
|

Menu

Close
X

miRagen Therapeutics Inc MGEN.OQ (NASDAQ Stock Exchange Capital Market)

5.59 USD
-0.02 (-0.36%)
As of 9:13 PM IST
chart
Previous Close 5.61
Open 5.60
Volume 10,773
3m Avg Volume 63,157
Today’s High 5.60
Today’s Low 5.52
52 Week High 17.83
52 Week Low 5.01
Shares Outstanding (mil) 21.48
Market Capitalization (mil) 202.81
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
3
FY16
4
FY15
3
EPS (USD)
FY17
-1.216
FY16
-21.598
FY15
-21.766
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
71.79
5.77
Price to Book (MRQ)
vs sector
4.91
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
9.31
16.52
LT Debt to Equity (MRQ)
vs sector
4.53
12.22
Return on Investment (TTM)
vs sector
-87.08
14.43
Return on Equity (TTM)
vs sector
-90.87
16.13

EXECUTIVE LEADERSHIP

William Marshall
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Jason Leverone
Chief Financial Officer, Treasurer, Secretary, Since 2017
Salary: --
Bonus: --
Paul Rubin
Executive Vice President - Research and Development, Since 2017
Salary: --
Bonus: --
Adam Levy
Chief Business Officer, Since 2017
Salary: --
Bonus: --
Bruce Booth
Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

6200 Lookout Rd
BOULDER   CO   80301-3319

Phone: +1303.5315952

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.

SPONSORED STORIES